Current Studies
This study is aimed at investigating variables in combination recanalization therapies for acute, large vessel ischemic stroke that are associated with better clinical outcomes (measured by NIH stoke scale and modified Rankin Scale). Identification of these variable could potentially improve...
View Details
Current Studies
Feasibility Research Objectives
For the purposes of the pilot phase, the primary objective will be to determine whether it is feasible to conduct a large multi-center RCT that will evaluate the impact of surveillance strategies on patient survival following extremity STS surgery. To do so, we will...
View Details
Current Studies
Primary Outcome Measures
Incidence of adverse events following administration of BBP-671 (Time Frame= 43 day)
BBP-671 concentration dependent change in change from baseline in QTcF (Time Frame= 43 days)
Pharmacokinetic Assessments: Cmax (Time Frame= 43 days)
Time to maximum concentration...
View Details
Current Studies
OBJECTIVES:
Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and treatment of pancreatic cancer by using the power of computer and informatics sciences.
Continue development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure to act as a...
View Details
Current Studies
The purpose of this study is to assess correlations between expression of blood serum biomarkers and cognitive impairment (CI) in patients with colorectal cancer throughout and following chemotherapy treatment. Our primary goal is to establish a panel of biomarkers that predict CI that can be...
View Details
Current Studies
Primary Outcome Measures :
Objective Response Rate (ORR) [ Time Frame: 24 months ]
ORR will be measured from the date of enrollment to date of progression (in months) based on RECIST 1.1 criteria. The analysis will include patients with PD-L1 expression TPS≥1-49 percent and TPS≥50...
View Details
Current Studies
Primary Outcome Measures:
*Safety of patient management pathway - Proportion of medication interventions with associated medication intervention related serious adverse events (Time Frame: Up to 3 years)
*The proportion of medication interventions with one or more associated medication...
View Details
Current Studies
PRIMARY OBJECTIVE
To assess the effect of in-hospital initiation of
dapagliflozin, as compared with placebo, on
the clinical outcomes of cardiovascular death
or worsening heart failure in patients who have been stabilized during
hospitalization for acute heart failure.
To evaluate the safety and...
View Details
Current Studies
Primary Objective: To determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the...
View Details
Current Studies
Primary:
* To identify risk factors in patient history among patients evaluated at the Fall Prevention Clinic.
Secondary:
* To compare the characteristics of adult patients who experience falls v/s those who do not.
* To review findings on examination (general and neurological) and testing...
View Details
Current Studies
Primary
The primary objective of this Phase 2 study is to evaluate the safety of Epcoritamab monotherapy without mandatory hospitalization for the first full dose of Epcoritamab in subjects with R/R DLBCL or R/R FL Grade 1-3a who have received at least 2 prior lines of systemic anti-lymphoma...
View Details
Current Studies
Aim of study: to examine outcomes and complications of rectal ESDs performed within 2 cm of the dentate line
Primary endpoints: to determine the rate of R0 resection of rectal ESDs performed within 2 cm of the dentate line
Secondary endpoints: to determine complication rates of rectal ESDs...
View Details
Current Studies
Our objective with this study is to take a retrospective look at patients with achalasia in the state of Indiana who have undergone either surgical therapy via laparoscopic or open Heller myotomy, or endoscopic therapy with the Per-oral endoscopic myotomy (POEM) procedure. We plan to compare the...
View Details
Current Studies
To offer NODE-301, NODE-302 and NODE-303 subjects continued access to Etripamil
View Details
Current Studies
Primary Objective
ctDNA-ve Cohort (Arms 1 + 2):
Phase II: To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. Time to positive event is defined as time from...
View Details
Current Studies
Primary objective
To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.
Secondary objective(s)
To evaluate and compare organ-preservation-time...
View Details
Current Studies
Primary Objective:
To evaluate the impact of Envisia on:
* Treatment decision: Increase in proportion of patients prescribed anti-fibrotics in those with an Envisia UIP+ result versus their pre-Envisia plan.
Secondary Objectives:
To evaluate the impact of Envisia on:
* Diagnosis: Increase in...
View Details
Current Studies
The primary objective is to evaluate whether invasive procedures in the group classified as low-risk by the Percepta Nasal Swab test and that are benign are reduced in the test group who received a Percepta Nasal Swab result as compared to the control group who were managed without a Percepta Nasal...
View Details
Current Studies
Primary Outcome Measures :
Time from randomization until treatment failure [ Time Frame: Randomization to until end of study (up to 39 months after randomization of last participant) ]
Time from randomization until treatment failure is defined as the time from randomization date until the first of...
View Details
Current Studies
Primary Objective:
* To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of death from coronary heart disease, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or...
View Details
Current Studies
Analyze the outcomes of endoscopic esophageal stent placement in those with esophageal cancer
View Details
Current Studies
The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R-CHOP followed by 2 cycles of epcoritamab (E + R-CHOP) can prolong PFS compared with 6 cycles of standard R-CHOP followed by 2 cycles of rituximab (R-CHOP) in subjects with newly...
View Details
Current Studies
Primary: Incidence and proportion of participants with selected Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: every visit up to 10 years after 1st dose of AAA617 received in parent treatment study ]
Selected AEs include xerostomia, xerophtalmia, myelosupression, renal...
View Details
Current Studies
Primary Objective:
To compare MK-2870 to Treatment of Physician s Choice (TPC) with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR)
To compare MK-2870 to TPC with respect to overall survival (OS)
Secondary Objectives:
To compare...
View Details
Current Studies
Primary: Determine the safety of a single administration of HMI-103
To evaluate the efficacy of HMI-103on reduction of plasma Pheconcentration at each dose level
View Details
Current Studies
Primary objective(s)
To demonstrate that either dose of ianalumab induces durable hemoglobin (Hb) response compared to placebo, in patients with wAIHA who failed at least one previous line of treatment
Secondary objective(s)
Key secondary objective: to demonstrate that either dose of ianalumab...
View Details
Current Studies
Primary Outcome Measures :
Time from randomization to treatment failure (TTF) [ Time Frame: Randomization to end of study (up to 39 months after randomization of last patient) ]
Time from randomization until platelet count below 30 G/L, need for a rescue treatment or start of a second-line therapy...
View Details
Current Studies
Primary Outcome Measures:
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
Secondoary Outcome...
View Details
Current Studies
Primary
Evaluate anti-tumor efficacy of VB10.16 + placebo and VB10.16 + Atezolizumab
Secondary
Further evaluate anti-tumor efficacy and response durability of VB10.16 + placebo and VB10.16 + atezolizumab
Evaluate clinical efficacy of VB10.16 + placebo and VB10.16 + atezolizumab
Characterize safety...
View Details
Current Studies
The primary endpoint of this post market registry study is to provide real-world evidence on the Composite Safety Success rate to enable meaningful comparison to other similar procedures. The Composite Safety Success rate is defined as the absence of Reoperation, Revision, Failure of Fixation,...
View Details
Current Studies
Demonstrate the Synergy Disc is at least as safe and effective
as conventional anterior cervical discectomy and fusion
(ACDF) to treat cervical degenerative disc disease (DDD) in
subjects who are symptomatic at two levels from C3 to C7 that
are unresponsive to conservative management.
View Details